Efficacy and Safety of LX9211 in Patients With Postherpetic Neuralgia (RELIEF-PHN1)

  • STATUS
    Recruiting
  • participants needed
    74
  • sponsor
    Lexicon Pharmaceuticals
Updated on 2 October 2022
herpes
rash

Summary

Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.

Details
Condition Postherpetic Neuralgia
Treatment Placebo, LX9211
Clinical Study IdentifierNCT04662281
SponsorLexicon Pharmaceuticals
Last Modified on2 October 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note